Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated September 19, 2024 (before its estimated November 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Re-verified, no change to tracked fieldsv4
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 12 of 12 sites
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomised, double blind, parallel group, multicentre study to compare the pharmacokinetics, pharmacodynamics, immunogenicity and safety of Rituximab (Mabscale LLC, Russia) versus MabThera® in patients with rheumatoid arthritis.
Trial Details
NCT Number NCT06175338
Lead Sponsor Mabscale, LLC
Conditions
(from sponsor)		 Rheumatoid Arthritis
Related terms Arthritis, Rheumatoid
Enrollment 208 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov